Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (51-60 of 120) with videos related to

Pageof 12
Sort By:
AIDS Reviews|March 11, 2010
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infectionGraeme Moyle, Michel Moutschen, Esteban Martínez, et al.
HIV Medicine|September 20, 2021
FRAX assessment in people ageing with HIVMaria Mazzitelli, Pereira Branca Isabel, Takashi Muramatsu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
The Clinical Journal of Pain|September 6, 2017
Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety StudyRafael Gálvez, Marie-Louise Navez, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intakeEmilie Elliot, Alieu Amara, Akil Jackson, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
AIDS Patient Care and Stds|March 13, 2012
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyCheryl McDonald, Jonathan Uy, Wenhua Hu, et al.
AIDS (London, England)|May 29, 2004
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendationsBonaventura Clotet, François Raffi, David Cooper, et al.
AIDS (London, England)|July 1, 2011
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished dataMario Cruciani, Veronica Zanichelli, Giovanni Serpelloni, et al.
Pageof 12

Showing results (51-60 of 120) with videos related to

Sort By:
Pageof 12
AIDS Reviews|March 11, 2010
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infectionGraeme Moyle, Michel Moutschen, Esteban Martínez, et al.
HIV Medicine|September 20, 2021
FRAX assessment in people ageing with HIVMaria Mazzitelli, Pereira Branca Isabel, Takashi Muramatsu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 1, 2013
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and preventionAkil Jackson, Graeme Moyle, Victoria Watson, et al.
The Clinical Journal of Pain|September 6, 2017
Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety StudyRafael Gálvez, Marie-Louise Navez, Graeme Moyle, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intakeEmilie Elliot, Alieu Amara, Akil Jackson, et al.
Antiviral Therapy|December 3, 2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessationMarta Boffito, Laura Else, David Back, et al.
Antimicrobial Agents and Chemotherapy|June 29, 2011
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessationMarta Boffito, Akil Jackson, Alieu Amara, et al.
AIDS Patient Care and Stds|March 13, 2012
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE studyCheryl McDonald, Jonathan Uy, Wenhua Hu, et al.
AIDS (London, England)|May 29, 2004
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendationsBonaventura Clotet, François Raffi, David Cooper, et al.
AIDS (London, England)|July 1, 2011
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished dataMario Cruciani, Veronica Zanichelli, Giovanni Serpelloni, et al.
Pageof 12